Piramal Pharma plans to double its turnover to $2 billion by 2030, focusing on its CDMO business and high-growth sectors like complex hospital generics and consumer healthcare. The company aims for significant revenue growth and improved EBITDA margins through strategic investments, expansions, and leveraging cost-efficient manufacturing infrastructure in India.
Related Posts
Now, SEBI investigating whether Adani Group flouted disclosure rules
The Securities and Exchange Board of India has asked officials at the stock exchanges if Adani Green Energy Ltd. failed to properly disclose the US […]
Reliance signs 10-yr deal with Russia’s Rosneft for $12-13bn a year oil import
Reliance Industries has inked a significant deal with Russia’s Rosneft, securing up to 500,000 barrels of crude oil daily for the next decade. This $12-13 […]